Glycemic management on systemic glucocorticoid therapy: more data needed

  • Tatalovic M & al.
  • BMJ Open
  • 1 Jun 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Achieving effective glycemic control in patients with type 2 diabetes (T2D) initiating systemic glucocorticoid therapy is difficult.
  • Obstacles include heterogeneity of populations, interventions, target glucose levels, and glucose monitoring in available studies, and low-moderate quality of evidence.
  • Even for the widely recommended basal-bolus insulin (BBI) regimens, data are inconclusive.

Why this matters

  • Steroid treatment in patients with diabetes is common, but often leads to or exacerbates hyperglycemia.

Study design

  • Systematic literature review yielded 8 articles reporting studies including 481 individuals (343 with diabetes, 138 with glucocorticoid-induced hyperglycemia).
  • Funding: None.

Key results

  • In 6 studies of BBI regimens, divergence in designs (i.e., in use of sliding-scale insulin [SSI] regimens, intermediate- vs long-acting insulin, and dosing) “precluded a clean and coherent quantitative meta-analysis.”  
  • In 3 trials comparing NPH with glargine in BBI regimens, overall glycemic control did not differ significantly between them.   
  • In 1 study comparing addition of SSI or intermediate-acting insulin (IMI) to established diabetes medication, IMI produced greater time in target glucose range (P<.001 and lower mean daily glucose>
  • No studies compared anticipatory vs compensatory adjustments.

Limitations

  • Low-moderate evidence quality.
  • Lack of comparability.
  • Inclusion of populations with type 1 diabetes, and T2D with and without baseline insulin treatment.